Literature DB >> 35051616

LncRNA IFITM4P promotes immune escape by up-regulating PD-L1 via dual mechanism in oral carcinogenesis.

Linjun Shi1, Yuquan Yang2, Mengying Li2, Chenxi Li1, Zengtong Zhou1, Guoyao Tang1, Lan Wu1, Yilin Yao1, Xuemin Shen3, Zhaoyuan Hou4, Hao Jia5.   

Abstract

Oral squamous cell carcinoma (OSCC), which is typically preceded by oral leukoplakia (OL), is a common malignancy with poor prognosis. However, the signaling molecules governing this progression remain to be defined. Based on microarray analysis of genes expressed in OL and OSCC samples, we discovered that the long non-coding RNA IFITM4P was highly expressed in OSCC, and ectopic expression or knockdown of IFITM4P resulted in increased or decreased cell proliferation in vitro and in xenografted tumors, respectively. Mechanistically, in the cytoplasm IFITM4P acted as a scaffold to facilitate recruiting SASH1 to bind and phosphorylate TAK1 (Thr187), and in turn to increase the phosphorylation of nuclear factor κB (Ser536) and concomitant induction of PD-L1 expression, resulting in activation of an immunosuppressive program that allows OL cells to escape anti-cancer immunity in cytoplasm. In nucleus, IFITM4P reduced Pten transcription by enhancing the binding of KDM5A to the Pten promoter, thereby upregulating PD-L1 in OL cells. Moreover, mice bearing tumors with high IFITM4P expression had notable therapeutic sensitivity to PD-1 monoclonal antibody (mAb) treatment. Collectively, these data demonstrate that IFITM4P may serve as a new therapeutic target in blockage of oral carcinogenesis, and PD-1 mAb can be an effective reagent to treat OSCC.
Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  IFITM4P; NF-κB; PD-L1/PD-1; PTEN; SASH1; TAK1; immune escape; lncRNA; oral leukoplakia; oral squamous cell carcinoma

Mesh:

Substances:

Year:  2022        PMID: 35051616      PMCID: PMC9077312          DOI: 10.1016/j.ymthe.2022.01.003

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   12.910


  51 in total

1.  The 4-NQO mouse model: An update on a well-established in vivo model of oral carcinogenesis.

Authors:  J Bouaoud; G De Souza; C Darido; A Tortereau; M Elkabets; C Bertolus; P Saintigny
Journal:  Methods Cell Biol       Date:  2020-11-12       Impact factor: 1.441

2.  Long non-coding RNAs are expressed in oral mucosa and altered in oral premalignant lesions.

Authors:  Ewan A Gibb; Katey S S Enfield; Greg L Stewart; Kim M Lonergan; Raj Chari; Raymond T Ng; Lewei Zhang; Calum E MacAulay; Miriam P Rosin; Wan L Lam
Journal:  Oral Oncol       Date:  2011-08-10       Impact factor: 5.337

3.  Enhancing KDM5A and TLR activity improves the response to immune checkpoint blockade.

Authors:  Liangliang Wang; Yan Gao; Gao Zhang; Dan Li; Zhenda Wang; Jie Zhang; Leandro C Hermida; Lei He; Zhisong Wang; Jingwen Si; Shuang Geng; Rizi Ai; Fei Ning; Chaoran Cheng; Haiteng Deng; Dimiter S Dimitrov; Yan Sun; Yanyi Huang; Dong Wang; Xiaoyu Hu; Zhi Wei; Wei Wang; Xuebin Liao
Journal:  Sci Transl Med       Date:  2020-09-09       Impact factor: 17.956

4.  Microsomal prostaglandin E synthase-1 is overexpressed in head and neck squamous cell carcinoma.

Authors:  Erik G Cohen; Taghreed Almahmeed; Baoheng Du; Dragan Golijanin; Jay O Boyle; Robert A Soslow; Kotha Subbaramaiah; Andrew J Dannenberg
Journal:  Clin Cancer Res       Date:  2003-08-15       Impact factor: 12.531

5.  Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack.

Authors:  Miroslaw J Szczepanski; Malgorzata Czystowska; Marta Szajnik; Malgorzata Harasymczuk; Michael Boyiadzis; Aleksandra Kruk-Zagajewska; Witold Szyfter; Jan Zeromski; Theresa L Whiteside
Journal:  Cancer Res       Date:  2009-03-24       Impact factor: 12.701

6.  Targeting of CD40 and PD-L1 Pathways Inhibits Progression of Oral Premalignant Lesions in a Carcinogen-induced Model of Oral Squamous Cell Carcinoma.

Authors:  Jose A Monteiro de Oliveira Novaes; Taghreed Hirz; Irene Guijarro; Monique Nilsson; Marlese A Pisegna; Alissa Poteete; Hampartsoum B Barsoumian; Jared J Fradette; Limo N Chen; Don L Gibbons; Xiangjun Tian; Jing Wang; Jeffrey N Myers; Mark J McArthur; Diana Bell; William N William; John V Heymach
Journal:  Cancer Prev Res (Phila)       Date:  2020-12-04

7.  BAY 11-7082 is a broad-spectrum inhibitor with anti-inflammatory activity against multiple targets.

Authors:  Jaehwi Lee; Man Hee Rhee; Eunji Kim; Jae Youl Cho
Journal:  Mediators Inflamm       Date:  2012-06-15       Impact factor: 4.711

8.  Exploring the molecular pathogenesis and biomarkers of high risk oral premalignant lesions on the basis of long noncoding RNA expression profiling by serial analysis of gene expression.

Authors:  Hongcheng Jia; Xuan Wang; Zheng Sun
Journal:  Eur J Cancer Prev       Date:  2018-07       Impact factor: 2.497

9.  Contributions of T cell dysfunction to the resistance against anti-PD-1 therapy in oral carcinogenesis.

Authors:  Liling Wen; Huanzi Lu; Qiusheng Li; Qunxing Li; Shuqiong Wen; Dikan Wang; Xi Wang; Juan Fang; Jun Cui; Bin Cheng; Zhi Wang
Journal:  J Exp Clin Cancer Res       Date:  2019-07-10

Review 10.  Regulation of PD-L1 Expression by NF-κB in Cancer.

Authors:  Fabrizio Antonangeli; Ambra Natalini; Marina Chiara Garassino; Antonio Sica; Angela Santoni; Francesca Di Rosa
Journal:  Front Immunol       Date:  2020-11-25       Impact factor: 7.561

View more
  4 in total

1.  Inhibition of ITGB1-DT expression delays the growth and migration of stomach adenocarcinoma and improves the prognosis of cancer patients using the bioinformatics and cell model analysis.

Authors:  Ni Jiang; Qiang Guo; Qing Luo
Journal:  J Gastrointest Oncol       Date:  2022-04

Review 2.  Oncogenic roles of the lncRNA LINC00460 in human cancers.

Authors:  Min Su; Jinming Tang; Desong Yang; Zhining Wu; Qianjin Liao; Hui Wang; Yuhang Xiao; Wenxiang Wang
Journal:  Cancer Cell Int       Date:  2022-07-29       Impact factor: 6.429

Review 3.  Current insight into the regulation of PD-L1 in cancer.

Authors:  Zhuandi Liu; Xibao Yu; Ling Xu; Yangqiu Li; Chengwu Zeng
Journal:  Exp Hematol Oncol       Date:  2022-07-30

Review 4.  Epigenetic modifications: Critical participants of the PD‑L1 regulatory mechanism in solid tumors (Review).

Authors:  Xiaoran Ma; Jibiao Wu; Bin Wang; Cun Liu; Lijuan Liu; Changgang Sun
Journal:  Int J Oncol       Date:  2022-09-21       Impact factor: 5.884

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.